Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

NVL-330

Small molecule · Inhibitor of HER2 (ERBB2) · developed by Nuvalent

Phase 1 Most advanced trial
NUVL Developer
1 Registered trials

What is NVL-330?

NVL-330 is an orally bioavailable, mutant-selective inhibitor of HER2 that targets HER2 exon20 insertion mutations, activating point mutations, and amplified wild-type HER2. It inhibits HER2-mediated signaling and can penetrate the blood-brain barrier. It is studied in locally advanced and metastatic solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
HER2 (ERBB2)
Mechanism
Inhibitor of HER2 (ERBB2)
Pathways
MAPK/ERK, PI3K/Akt, angiogenesis
Therapy area
Oncology
Developer
Nuvalent Inc. (NUVL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06521554 Phase 1 Locally Advanced Solid Tumor Recruiting NUVL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Locally Advanced Solid TumorMetastatic Solid Tumor

Other drugs acting on ERBB2

Neratinib FDA approved Trastuzumab Deruxtecan FDA approved Trastuzumab Emtansine FDA approved Zanidatamab FDA approved ADCT-502 Phase 1 BH-30643 Phase 1/2 CGT4255 Phase 1 CUDC-101 Phase 1 ELVN-002 Phase 1 Enozertinib Phase 1/2 TTX-MC138 Phase 1/2 Tuxobertinib Phase 1

More from Nuvalent

Zidesamtinib FDA approved NVL-655 Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the NUVL page.

Follow NUVL, the company behind NVL-330

See NUVL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NUVL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.